Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by MiNK Therapeutics

MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Therapeutics Reports Third Quarter 2024 Results and Business Update
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK’s iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Therapeutics to Participate in H.C. Wainwright Global Investment Conference
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Reports Second Quarter 2024 Results and Business Update
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Therapeutics Regains Compliance with Nasdaq Capital Market Requirement
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Reports First Quarter 2024 Results
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK to Provide Corporate Update and First Quarter 2024 Financial Report
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Reports Fourth Quarter and Year-End 2023 Results
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and Balstilimab
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK’s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Therapeutics Reports Third Quarter 2023 Results
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK to Provide Third Quarter 2023 Financial Report and Corporate Update
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Therapeutics To Present Data Update From Allogeneic iNKT Cells in Solid Tumors at SITC 2023
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Therapeutics to Participate in September Investor Conferences
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Therapeutics Reports Second Quarter 2023 Results
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.